Clinical Trial

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2025 (before its estimated December 9, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-01; most recent amendment 2025-12-02.
Trial Details
NCT Number NCT05636579
Lead Sponsor Asociación para Evitar la Ceguera en México
Collaborators: Emmecell
Conditions Corneal Edema, Corneal Endothelial Dystrophy, Endothelial Dysfunction, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Bullous Keratopathy, Pseudophakic Bullous Keratopathy, Corneal Edema Pseudophakic
Enrollment 12 participants
Start Date 2022-11-08
Primary Completion 2025-12-09 (estimated)
Study Completion 2025-12-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-08